Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

San Francisco, California-- (Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

Join Lee Rennick from the CIO100 with Bob McCowan, SVP & CIO, Regeneron as he discusses the award-winning Centralized Data ...

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

Forty high school students, including four from Nassau County, have been selected as finalists for the annual Regeneron ...

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look ...

Regeneron Pharmaceuticals Inc. closed 43.47% below its 52-week high of $1,211.20, which the company achieved on August 27th.

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...